Altimmune, Inc. Stock News

The stock price of Altimmune, Inc. (Nasdaq: ALT) increased by 16.49% yesterday. This is why it happened.

Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre

Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was

An experimental new weight loss drug produced compelling data in an early stage clinical trial.

GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of i

Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine neutralized the COVID-19 B.1.351 varia

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

Altimmune: Managing A Position Around A Critical AdCOVID Readout

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing intranasal vaccines, immune-modulating therapies, and treatments for liver disease. Altimmune's pipeline consists of intranasal

Altimmune, Inc.'s (ALT) CEO Vipin Garg on Q1 2021 Results - Earnings Call Transcript

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.56% and -61.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial resu

Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection. The

Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.